Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

146.17 +1.48 (+1.02%)
Streaming Delayed Price Updated: 2:10 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
55 56 Next >
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
From Biogen Inc.
Via GlobeNewswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Is Biogen Stock a Buy Now?
Its revenue now has a plausible path to doubling, but risks remain high. 
Via The Motley Fool
CrowdStrike (CRWD) Stock Sinks on Weak Guidance
CrowdStrike (CRWD) stock is falling on Wednesday following the release of its earnings report for the third quarter of 2022. 
Via InvestorPlace
26 Analysts Have This to Say About Biogen
 
Via Benzinga
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
These stocks have climbed by double digits this year. 
Via The Motley Fool
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
From Biogen Inc.
Via GlobeNewswire
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
Why 2023 Could Be a Big Year for Biogen
Investors will soon learn if the company's Alzheimer's treatment gets the green light. 
Via The Motley Fool
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
From Biogen Inc.
Via GlobeNewswire
Even After This Year’s Melt-Up, Runway Remains for LLY Stock
The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making. 
Via InvestorPlace
Can These 2 Stocks Crush the Market Again in 2023?
Both are riding the wave of major clinical wins 
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). 
Via Benzinga
BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen
Biogen (BIIB) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate. 
Via InvestorPlace
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
 
Via Benzinga
Biogen Stock Is Surging Today: What's Going On?
Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's 
Via Benzinga
Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday
Mizuho cut Alphabet Inc. (NASDAQ: GOOGL) price target from $140 to $135. Mizuho analyst James Lee maintained a Buy rating on the stock. Alphabet shares gained 0.4% to $95.53 in pre-market trading. 
Via Benzinga
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors
The update from Eisai suggests there is a benefit question ahead of the companies. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies. 
Via Investor's Business Daily
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that... 
Via Benzinga
Market Currents: Why Pick Stocks?
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and... 
Via Talk Markets
2 Stocks Near 52-Week Highs That Could Climb Higher
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400. 
Via TheNewswire.com
Topics ETFs Economy Stocks
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
By Jad Malaeb, Benzinga 
Via News Direct
Topics ETFs Economy
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.